Kenneth A. Jamerson, MD, a prominent figure in national and international healthcare, is a Professor of Internal Medicine and the Frederick G.L. Huetwell Collegiate Professor of Cardiovascular Medicine at the University of Michigan Medical School.

Dr. Jamerson is an advisor to national and international clinical trials that examines the impact of hypertension control on global populations. Dr. Jamerson is a microbiologist with an initial research focus on the role of the sympathetic nervous system’s impact on blood flow and glucose transport in human skeletal muscle. His current research continues to focus on factors associated with metabolic syndrome.

Dr. Jamerson has served as coordinator and principal investigator for numerous multi-center clinical trials nationally and internationally sponsored by NIH and industry, including a landmark trial that sought to optimize medical management in Africans Americans with kidney disease. Recently, he was the principal investigator for the first international study with more than 11,000 subjects to determine the impact of optimal combination therapy strategies. He is funded by the NIH to assess factors that predict both renal and cardiovascular disease in patients with chronic kidney disease. He is also a part of a NIH-funded team to investigate the role of renal artery revascularization on cardiovascular outcomes. He serves in an executive or advisory role in a number of multi-center cardiovascular outcomes trials funded by both federal and industry sponsors.

Dr. Jamerson is a past-president of ISHIB, an international organization devoted to ethnicity and disease. In this role his research included addressing the perceptions, barriers and behaviors that may affect health care disparity. In a novel investigation, Dr. Jamerson, with investigators from the Institute for Social Research at the University of Michigan, describe how these factors affect African American’s participation in clinical trials. He is part of a multi-disciplinary team using cognitive theory for behavior modification strategies. The first study of its kind, resulted in participants' long-term loss of weight, decrease in blood pressure, and lowered cholesterol levels, with the benefits persisting for nearly a year after the initial intervention.

Dr. Jamerson has authored a number of scientific articles and has presented his research both nationally and internationally. He serves on Editorial Boards and peer-reviewer of several prominent journals. He has served as a member of study sections, safety and data monitoring boards, and advisory panels for both the Heart and Kidney Institutes at the NIH. He serves as a member and in leadership roles in a number of medical and scientific societies. He is the recipient of several awards in community service and teaching.

Dr. Jamerson obtained his medical degree from the University of Michigan in Ann Arbor, where he completed his internal medicine residency and held a fellowship in hypertension research